These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30233142)

  • 1. The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules.
    Pavloff N; Hauser TA; Williams C; Isbell SL; Cadieux B; Johnson M
    Drug Des Devel Ther; 2018; 12():2795-2804. PubMed ID: 30233142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
    Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
    Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
    Langman CB
    Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
    Medic G; van der Weijden M; Karabis A; Hemels M
    Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
    Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
    Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.
    Gangoiti JA; Fidler M; Cabrera BL; Schneider JA; Barshop BA; Dohil R
    Br J Clin Pharmacol; 2010 Sep; 70(3):376-82. PubMed ID: 20716238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients.
    Kishk OA; Kim I; Cheng C; Summan M; Muñoz MA
    Pediatr Nephrol; 2024 Aug; 39(8):2429-2433. PubMed ID: 38462547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the treatment of cystinosis.
    Schneider JA; Clark KF; Greene AA; Reisch JS; Markello TC; Gahl WA; Thoene JG; Noonan PK; Berry KA
    J Inherit Metab Dis; 1995; 18(4):387-97. PubMed ID: 7494398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic Studies of Cysteamine Bitartrate Delayed-Release.
    Dohil R; Rioux P
    Clin Pharmacol Drug Dev; 2013 Apr; 2(2):178-85. PubMed ID: 27121672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding.
    Wells KA; Losin WG
    Clin Ther; 2008 Jul; 30(7):1300-8. PubMed ID: 18691989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
    Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
    J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cysteamine bitartrate delayed-release capsules control leukocyte cystine levels and promote statural growth and kidney health in an open-label study of treatment-naïve patients <6 years of age with nephropathic cystinosis.
    Vaisbich MH; Caires Ferreira J; Price H; Young KD; Sile S; Checani G; Langman CB
    JIMD Rep; 2022 Jan; 63(1):66-79. PubMed ID: 35028272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
    Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term treatment of cystinosis in children with twice-daily cysteamine.
    Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
    J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
    Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
    Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
    Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
    van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
    Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
    Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
    J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
    Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
    Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum: The effect of food and liquid pH on the integrity of enteric-coated beads from cysteamine bitartrate delayed-release capsules [Corrigendum].
    Drug Des Devel Ther; 2018; 12():3797. PubMed ID: 30464410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.